2023-506038-65-00
CTIS ↗
BDC-1001, PERTUZUMAB
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER
pharma · HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER · Advanced HER2-Expressing Solid Tumors. · BOLT
Bolt Biotherapeutics
Bolt Biotherapeutics trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.
Redwood City, USA HQ
2015 Founded
51 Employees
Public company Type
BOLT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Founded
- 2015
- Employees
- 51
- Programs
- 6
- Drugs
- 4
- Patents
- 7
Bolt Biotherapeutics clinical trials
Registry index of 6 ClinicalTrials.gov studies linked to Bolt Biotherapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Bolt Biotherapeutics trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Bolt Biotherapeutics.